JP2014503189A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503189A5 JP2014503189A5 JP2013535578A JP2013535578A JP2014503189A5 JP 2014503189 A5 JP2014503189 A5 JP 2014503189A5 JP 2013535578 A JP2013535578 A JP 2013535578A JP 2013535578 A JP2013535578 A JP 2013535578A JP 2014503189 A5 JP2014503189 A5 JP 2014503189A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- molecule
- composition
- human her3
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 27
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 101001010819 Homo sapiens Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 102000057750 human ERBB3 Human genes 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40878210P | 2010-11-01 | 2010-11-01 | |
| US61/408,782 | 2010-11-01 | ||
| DKPA201000988 | 2010-11-01 | ||
| DKPA201000988 | 2010-11-01 | ||
| DKPA201100672 | 2011-09-05 | ||
| DKPA201100672 | 2011-09-05 | ||
| US201161531407P | 2011-09-06 | 2011-09-06 | |
| US61/531,407 | 2011-09-06 | ||
| PCT/IB2011/054835 WO2012059858A1 (en) | 2010-11-01 | 2011-10-31 | Anti-her3 antibodies and compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503189A JP2014503189A (ja) | 2014-02-13 |
| JP2014503189A5 true JP2014503189A5 (enExample) | 2014-12-18 |
| JP6186277B2 JP6186277B2 (ja) | 2017-08-23 |
Family
ID=59014867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535577A Expired - Fee Related JP6033783B2 (ja) | 2010-11-01 | 2011-10-31 | Ｐａｎ−ｈｅｒ抗体組成物 |
| JP2013535578A Expired - Fee Related JP6186277B2 (ja) | 2010-11-01 | 2011-10-31 | 抗ｈｅｒ３抗体および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535577A Expired - Fee Related JP6033783B2 (ja) | 2010-11-01 | 2011-10-31 | Ｐａｎ−ｈｅｒ抗体組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9217039B2 (enExample) |
| EP (3) | EP2635605B1 (enExample) |
| JP (2) | JP6033783B2 (enExample) |
| KR (2) | KR101862832B1 (enExample) |
| AU (2) | AU2011324870B2 (enExample) |
| CA (2) | CA2816520C (enExample) |
| DK (1) | DK2635604T3 (enExample) |
| ES (2) | ES2616961T3 (enExample) |
| IL (2) | IL225954B (enExample) |
| MX (2) | MX347981B (enExample) |
| PL (1) | PL2635604T3 (enExample) |
| TW (1) | TW201231066A (enExample) |
| WO (2) | WO2012059857A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010022736A2 (en) * | 2008-08-29 | 2010-03-04 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| WO2010029534A1 (en) | 2008-09-15 | 2010-03-18 | Yeda Research And Development Co. Ltd. | Antibody combinations and use of same for treating cancer |
| RS54795B1 (sr) | 2009-12-22 | 2016-10-31 | Roche Glycart Ag | Anti-her3 antitela i njihova korišćenja |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| MX347981B (es) | 2010-11-01 | 2017-05-22 | Symphogen As | Composicion de anticuerpos pan-her. |
| MX2013010444A (es) * | 2011-03-15 | 2014-03-21 | Merrimack Pharmaceuticals Inc | Superar la resistencia a inhibidores de la via erbb. |
| EP2710038B1 (en) * | 2011-05-16 | 2018-01-17 | Yeda Research and Development Co. Ltd. | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER |
| PT2837680T (pt) * | 2011-07-01 | 2020-04-17 | Amgen Inc | Cultura celular de mamífero |
| DK2797957T3 (da) | 2011-11-23 | 2019-09-23 | Medimmune Llc | Bindingsmolekyler specifikke for her3 og anvendelser deraf |
| US20130259867A1 (en) * | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
| WO2013164689A2 (en) | 2012-05-02 | 2013-11-07 | Lantto, Johan | Humanized pan-her antibody compositions |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| JP6595458B2 (ja) | 2013-09-20 | 2019-10-23 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP3191523B1 (en) | 2014-09-08 | 2019-08-07 | Yeda Research and Development Co., Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| WO2016038609A1 (en) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| ES2748295T3 (es) | 2014-09-16 | 2020-03-16 | Symphogen As | Anticuerpos anti-MET y composiciones |
| EP3176183A1 (en) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| UA129904C2 (uk) | 2017-04-05 | 2025-09-10 | Ле Лаборатуар Сервьє | Комбінація антитіла до tim-3 й антитіла до pd-1 для лікування раку |
| ES2965352T3 (es) | 2017-05-30 | 2024-04-12 | Bristol Myers Squibb Co | Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3) |
| CN110678200B (zh) | 2017-05-30 | 2024-05-17 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| JP7654539B2 (ja) | 2018-09-07 | 2025-04-01 | ファイザー・インク | 抗αｖβ８抗体、組成物及びその使用 |
| CN114426578B (zh) * | 2019-02-14 | 2025-03-21 | 美勒斯公司 | 结合egfr、her2及her3的结合部分的组合 |
| EP3924384A1 (en) * | 2019-02-14 | 2021-12-22 | Merus N.V. | Combinations of binding moieties that bind egfr, her2 and her3 |
| JP7774293B2 (ja) * | 2019-07-24 | 2025-11-21 | 国立研究開発法人科学技術振興機構 | 抗体酵素の革新的製造技術 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| KR20230093282A (ko) | 2020-10-23 | 2023-06-27 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 lag-3 길항제 요법 |
| TWI905354B (zh) | 2020-12-31 | 2025-11-21 | 法商英耐特醫藥公司 | 結合至NKp46及CD123之多功能自然殺手 (NK) 細胞接合體 |
| KR20250017240A (ko) | 2022-05-27 | 2025-02-04 | 사노피 | FC-조작을 갖는 NKp46 및 BCMA 변이체에 결합하는 자연 살해(NK) 세포 관여자 |
| EP4713360A1 (en) | 2023-05-19 | 2026-03-25 | Les Laboratoires Servier | Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69736806T3 (de) * | 1996-03-27 | 2015-10-08 | Genentech, Inc. | ErbB3 ANTIKÖRPER |
| US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| AUPQ105799A0 (en) * | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| SI1583830T1 (sl) | 2003-01-07 | 2006-12-31 | Symphogen As | Postopek za pripravo rekombinantnih poliklonskih proteinov |
| EP1609803A4 (en) * | 2003-03-31 | 2006-05-24 | Chugai Pharmaceutical Co Ltd | MODIFIED ANTIBODY AGAINST CD22 AND APPLICATIONS THEREOF |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| US8288109B2 (en) | 2004-07-20 | 2012-10-16 | Symphogen A/S | Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line |
| DK1771482T3 (da) | 2004-07-22 | 2014-10-20 | Genentech Inc | HER2-antistofsammensætning |
| WO2006063042A2 (en) | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| WO2008031531A1 (en) * | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| KR101598229B1 (ko) * | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| BRPI0808551B1 (pt) | 2007-03-01 | 2022-04-05 | Symphogen A/S | Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende |
| MX2009012526A (es) | 2007-05-25 | 2009-12-09 | Symphogen As | Metodo para fabricar una proteina policlonal recombinante. |
| RU2476886C2 (ru) | 2007-11-22 | 2013-02-27 | Симфоген А/С | Способ характеризации рекомбинантного поликлонального белка |
| NZ588651A (en) | 2008-04-23 | 2012-04-27 | Symphogen As | Methods for manufacturing a polyclonal protein |
| WO2010019952A2 (en) | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
| WO2010022736A2 (en) * | 2008-08-29 | 2010-03-04 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| BRPI0920032A2 (pt) | 2008-10-06 | 2017-06-27 | Symphogen As | método para identificar e selecionar candidatos a fármacos para produtos farmacológicos combinatórios |
| MY152068A (en) | 2009-03-20 | 2014-08-15 | Genentech Inc | Bispecific anti-her antibodies |
| SG175077A1 (en) | 2009-04-07 | 2011-11-28 | Roche Glycart Ag | Trivalent, bispecific antibodies |
| MX2011010166A (es) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
| EP2425009A4 (en) | 2009-04-29 | 2013-01-23 | Trellis Bioscience Llc | Improved antibodies immunoreactive with heregulin-coupled her3 |
| WO2011003780A1 (en) | 2009-07-06 | 2011-01-13 | F. Hoffmann-La Roche Ag | Bi-specific digoxigenin binding antibodies |
| EA201200195A1 (ru) * | 2009-08-21 | 2012-12-28 | Мерримаск Фармасьютикалс, Инк. | АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ |
| AU2010303443A1 (en) | 2009-10-09 | 2012-04-19 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-Her 3 antibodies |
| EP2896632B1 (en) | 2009-11-13 | 2017-10-25 | Daiichi Sankyo Europe GmbH | Material and methods for treating or preventing HER-3 associated diseases |
| CN102884084B (zh) | 2010-03-04 | 2016-12-07 | 西福根有限公司 | 抗her2抗体及组合物 |
| MX343227B (es) | 2010-04-09 | 2016-10-28 | Aveo Pharmaceuticals Inc | Anticuerpos anti-erbb3. |
| AU2011290672B2 (en) * | 2010-08-20 | 2015-07-09 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
| MX347981B (es) | 2010-11-01 | 2017-05-22 | Symphogen As | Composicion de anticuerpos pan-her. |
-
2011
- 2011-10-31 MX MX2013004899A patent/MX347981B/es active IP Right Grant
- 2011-10-31 WO PCT/IB2011/054834 patent/WO2012059857A2/en not_active Ceased
- 2011-10-31 KR KR1020137013561A patent/KR101862832B1/ko not_active Expired - Fee Related
- 2011-10-31 EP EP11837656.5A patent/EP2635605B1/en not_active Not-in-force
- 2011-10-31 DK DK11797354.5T patent/DK2635604T3/en active
- 2011-10-31 CA CA2816520A patent/CA2816520C/en not_active Expired - Fee Related
- 2011-10-31 AU AU2011324870A patent/AU2011324870B2/en not_active Ceased
- 2011-10-31 PL PL11797354T patent/PL2635604T3/pl unknown
- 2011-10-31 EP EP16200853.6A patent/EP3156421B1/en not_active Not-in-force
- 2011-10-31 AU AU2011324871A patent/AU2011324871B2/en not_active Ceased
- 2011-10-31 MX MX2013004897A patent/MX348637B/es active IP Right Grant
- 2011-10-31 WO PCT/IB2011/054835 patent/WO2012059858A1/en not_active Ceased
- 2011-10-31 US US13/882,807 patent/US9217039B2/en not_active Expired - Fee Related
- 2011-10-31 ES ES11797354.5T patent/ES2616961T3/es active Active
- 2011-10-31 KR KR1020137013552A patent/KR101773120B1/ko not_active Expired - Fee Related
- 2011-10-31 ES ES11837656.5T patent/ES2692379T3/es active Active
- 2011-10-31 EP EP11797354.5A patent/EP2635604B1/en not_active Not-in-force
- 2011-10-31 CA CA2816519A patent/CA2816519C/en not_active Expired - Fee Related
- 2011-10-31 JP JP2013535577A patent/JP6033783B2/ja not_active Expired - Fee Related
- 2011-10-31 JP JP2013535578A patent/JP6186277B2/ja not_active Expired - Fee Related
- 2011-11-01 TW TW100139897A patent/TW201231066A/zh unknown
-
2013
- 2013-04-25 IL IL225954A patent/IL225954B/en active IP Right Grant
- 2013-04-25 IL IL225953A patent/IL225953A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503189A5 (enExample) | ||
| JP2014503188A5 (enExample) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2020023523A5 (enExample) | ||
| RU2504553C2 (ru) | Антитела к her | |
| JP2017534259A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| RU2016115866A (ru) | Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи | |
| RU2014103784A (ru) | Антитело, блокирующее agr2, и его применение | |
| JP2013520984A5 (enExample) | ||
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| JP2018503380A5 (enExample) | ||
| JP2014509510A5 (enExample) | ||
| JP2010531140A5 (enExample) | ||
| FI3328888T3 (fi) | Anti-PSMA-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat PSMA:ta ja CD3:a, ja niiden käyttöjä | |
| SI2753646T1 (en) | Anti-CD40 antibodies, uses and methods | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| RU2014149553A (ru) | Биспецифические анти-vegf/анти-ang-2 антитела | |
| RU2014149681A (ru) | Антитела с множественной специфичностью | |
| JP2018509175A5 (enExample) | ||
| RU2013102225A (ru) | АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2013527761A5 (enExample) | ||
| JP2015501814A5 (enExample) | ||
| JP2009545325A5 (enExample) |